TBE/iStock Editorial via Getty Images
The US Court of Appeals has reportedly ruled that the whistleblower case v. Novartis (NYSE:NVS:) alleged kickbacks related to its multiple sclerosis drug Gilenya may continue.
The US Second Circuit Court of Appeals in Manhattan ruled that whistleblower Stephen Camburn can:
By Nate Raymond: (NSE:) BOSTON (Reuters) – Democratic-led states and civil rights groups filed a series…
OMRON reports Q3 results Report Thank you for Report Game / Application Name Your Email:…
Fox Business Contributor Katrina Campins joins the “Great Money Display”, commented on President Donald Trump’s “Quiet”…
The FAA is reported to discuss $ 2.4 billion agreement with Verencon to update its communication…
Picture of earnings. Conagra Brands FQ3 omisses evaluations. re-establishes FY25 Outlook Report Thank you for…
Nissan’s directors are of great interest to the candidates to succeed in Makoto Uvida by a…
English